Ourania Tatsis Sells 1,500 Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Ourania Tatsis sold 1,500 shares of the company’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $524.99, for a total value of $787,485.00. Following the completion of the transaction, the executive vice president owned 45,321 shares of the company’s stock, valued at $23,793,071.79. The trade was a 3.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vertex Pharmaceuticals Trading Down 4.6%

NASDAQ VRTX opened at $498.43 on Thursday. The business’s 50-day moving average price is $454.55 and its 200 day moving average price is $457.86. Vertex Pharmaceuticals Incorporated has a twelve month low of $362.50 and a twelve month high of $533.67. The company has a market capitalization of $126.50 billion, a PE ratio of 29.56, a price-to-earnings-growth ratio of 2.23 and a beta of 0.29.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 EPS for the quarter, beating the consensus estimate of $4.24 by $0.23. Vertex Pharmaceuticals had a return on equity of 23.86% and a net margin of 35.51%.The company had revenue of $2.99 billion during the quarter, compared to analysts’ expectations of $2.99 billion. During the same quarter in the previous year, the business earned $4.06 EPS. The firm’s revenue was up 8.3% on a year-over-year basis. Equities analysts predict that Vertex Pharmaceuticals Incorporated will post 17.02 EPS for the current year.

Trending Headlines about Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: The Crinetics deal could broaden Vertex’s growth profile, giving it immediate revenue from PALSONIFY and adding Atumelnant, a Phase 3 asset in congenital adrenal hyperplasia. Vertex to Acquire Crinetics Pharmaceuticals
• Positive Sentiment: Analysts and market commentary continue to frame the acquisition as a strategic fit that strengthens Vertex’s rare-disease pipeline and supports longer-term revenue diversification. Vertex’s Crinetics Deal Balances Growth with Integration Risk
• Positive Sentiment: Several broker notes remain constructive on VRTX, including Citi and other firms reiterating bullish views after the deal announcement. Citi Remains a Buy on Vertex Pharmaceuticals (VRTX)
• Neutral Sentiment: Vertex also disclosed a pre-planned insider stock sale, but the transaction was made under a Rule 10b5-1 plan, so it is unlikely to be read as a fundamental warning sign. SEC filing for Ourania Tatsis
• Negative Sentiment: Some investors appear cautious about the size of the cash deal, integration execution, and whether Vertex is paying a full price, which may be putting pressure on the shares. Crinetics Pharmaceuticals Investor Alert

Institutional Trading of Vertex Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Brighton Jones LLC lifted its position in Vertex Pharmaceuticals by 15.0% during the fourth quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock valued at $1,783,000 after buying an additional 579 shares in the last quarter. Gamco Investors INC. ET AL acquired a new stake in shares of Vertex Pharmaceuticals in the second quarter worth $228,000. NewEdge Advisors LLC raised its stake in shares of Vertex Pharmaceuticals by 9.0% in the 2nd quarter. NewEdge Advisors LLC now owns 11,929 shares of the pharmaceutical company’s stock valued at $5,311,000 after acquiring an additional 986 shares during the period. ICW Investment Advisors LLC lifted its holdings in shares of Vertex Pharmaceuticals by 5.0% during the 2nd quarter. ICW Investment Advisors LLC now owns 604 shares of the pharmaceutical company’s stock valued at $269,000 after acquiring an additional 29 shares in the last quarter. Finally, Diversify Advisory Services LLC lifted its holdings in shares of Vertex Pharmaceuticals by 26.3% during the 2nd quarter. Diversify Advisory Services LLC now owns 7,291 shares of the pharmaceutical company’s stock valued at $3,246,000 after acquiring an additional 1,518 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on VRTX. Royal Bank Of Canada upped their price target on shares of Vertex Pharmaceuticals from $543.00 to $570.00 and gave the stock an “outperform” rating in a research report on Tuesday. Morgan Stanley lifted their price target on shares of Vertex Pharmaceuticals from $612.00 to $616.00 and gave the company an “overweight” rating in a report on Tuesday, May 5th. Weiss Ratings cut shares of Vertex Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, June 30th. Wall Street Zen downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, June 28th. Finally, Sanford C. Bernstein cut their target price on Vertex Pharmaceuticals from $577.00 to $572.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 5th. Twenty-one analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $557.09.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.